|Videos|April 22, 2021
Emerging Front-Line Maintenance Therapies for Advanced Ovarian Cancer
Author(s)Rebecca Previs, MD
Dr. Rebecca Previs shares data on some exiting emerging therapies in the front line setting for patients with advanced ovarian cancer.
Advertisement
Advertisement
Related to this article
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Acting on a HER2 Result and Navigating Access to Therapy
3
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
4
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
5